Studies have demonstrated that LXR activation inhibits AD-related inflammatory responses and inflammatory gene expression, owing to LXR's ability to functionally inactivate the promoters of pro-inflammatory genes and of nuclear factor-κB (NF-κB) [73]–[78]. The gene discussed is NFKB1; the disease is Alzheimer disease.